相关实验视频
Updated: Jan 16, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
时间到组合疗法:高风险心脏瘤病患者的SGLT2i和PCSK9i
Vincenzo Quagliariello1, Massimiliano Berretta2, Irma Bisceglia3
1Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Napoli, Italia.
癌症幸存者面临高心脏代谢风险. 结合-葡萄糖共运输体2抑制剂 (SGLT2i) 和PCSK9抑制剂,可以提供对这些相互关联的风险的协同保护.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 代谢性疾病是一种代谢性疾病.
- 心血管方面的并发症.
背景情况:
- 癌症幸存者面临由心脏代谢并发症增加的发病率和死亡率.
- 共同的机制将癌症,脂质失调,胰岛素抵抗和炎症联系在一起,加速动脉样硬化和心力衰竭.
- 心脏毒性疗法加剧高血糖和高脂血症,导致长期幸存者的心血管不良后果.
研究的目的:
- 建议使用SGLT2抑制剂和PCSK9抑制剂的组合策略,用于管理癌症幸存者的心脏代谢风险.
- 探索SGLT2i和PCSK9i在减轻双重瘤和心血管风险方面的潜在协同作用.
主要方法:
- 对SGLT2抑制剂和PCSK9抑制剂在降低心血管风险方面的现有文献的综述.
- 分析癌症和心脏代谢疾病之间共享的病理生理路径.
- 假设一种针对葡萄糖和脂质代谢,炎症和器官重塑的组合治疗方法.
主要成果:
- SGLT2 抑制剂在心力衰竭,脏保护和血糖控制方面显示出好处.
- PCSK9抑制剂显著降低了LDL胆固醇,并表现出抗炎作用.
- 结合SGLT2i和PCSK9i的策略可以提供对复杂心脏代谢风险的协同保护.
结论:
- 综合SGLT2i和PCSK9i治疗有望重新定义高风险心脏瘤病患者的护理.
- 这种组合方法针对多个机制性途径,解决相互交织的葡萄糖和脂质失调.
- 需要进一步的临床试验来验证这一策略,并建立最佳的治疗方案.
更多相关视频
08:14A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Coronary Artery Disease V: Interprofessional Care
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drug Dosing: Obese Patients
Acute Coronary Syndrome IV: Interprofessional Care
Cardiomyopathy V: Interprofessional Care